Kenya Allergy Therapeutics Market Analysis

Kenya Allergy Therapeutics Market Executive Summary

Kenya Allergy Therapeutics Market was valued at $16 Mn in 2022 and is estimated to reach $29 Mn in 2030, exhibiting a CAGR of 7.5% during the forecast period.

Allergens are substances found in the environment that can occasionally cause allergic reactions in the body. Common allergies comprise items such as dust mites, pollen, and mildew, as well as specific foods like milk, eggs, soy, and almonds. Allergies can cause a wide range of symptoms, from minor ones like a runny nose and itchy eyes to serious ones like anaphylaxis, which is marked by unconsciousness and breathing problems. Medications such as antihistamines and nasal corticosteroids can be prescribed, while immunotherapy and allergen avoidance techniques are viable forms of treatment.

An estimated 13.8% of school-age children in Kenya are expected to have bronchial asthma, which is a rather high percentage when compared to certain other nations and possibly lower than rates seen in Western nations. Specifically, in this case, allergens such as peanuts and cow's milk may be more common causes of asthma. Furthermore, skin allergies, specifically atopic dermatitis or eczema, are very common in Kenya, especially in young people. These allergy patterns are caused by a variety of variables, including environmental factors like pollen, dust mites, and air pollution. A family history of allergies might increase the risk, so genetics also play a part. Research on how dietary and lifestyle factors may affect the prevalence of allergies is still underway. Moreover, geographical disparities within Kenya, resulting from changes in temperature, pollution levels, and dietary practices, could also be a factor in the wide range of allergy prevalence rates observed throughout the nation. Recently, Mepharm Kenya Ltd. announced plans to collaborate with a research institute to develop a new antihistamine medicine that will be produced domestically. The company highlighted the medication's potential affordability benefits, specifically for the Kenyan market. This program demonstrates Mepharm's constant commitment to research and development in line with regional healthcare needs.

Pharmanet Kenya Ltd. made a big move by expanding its capacity to produce nasal corticosteroids and generic antihistamines, with the main objective being to improve the availability and cost-effectiveness of allergy drugs in Kenya.

Market Dynamics

Market Growth Drivers

Rising Incidence of Allergies: Allergies impact a huge percentage of the population, especially those with respiratory diseases like asthma and allergic rhinitis. These diseases may be becoming more common due to factors including dust mites, changing dietary patterns, and environmental pollutants.

Shifting Treatment Trends: The increasing need for personalized medical plans that take into account the unique demands and triggers of each patient may open up new markets for tailored allergy treatment alternatives. The market is growing as a result of the growing use of telehealth platforms, which facilitate better access to physicians and prescription medications.

Urbanization and Changing Lifestyles: The trend toward an increase in the need for allergy treatment pharmaceuticals is mostly being driven by urbanization and changes in lifestyle, such as greater exposure to indoor allergens such dust mites and outdoor pollutants.

Market Restraints

High Cost of Treatment: Treatments for allergies can be quite expensive for certain patients, particularly if they involve Allergen Immunotherapy methods such as immunotherapy injections and SLIT tablets. Allergy drugs high cost may prohibit people from using and accessing them broadly, which would restrict their market penetration.

Regulatory Challenges: Navigating the regulatory landscape for the importation and registration of innovative allergy medicines is a challenging and time-consuming task for pharmaceutical companies. This complexity can prevent the market from growing as it impedes the timely introduction of fresh therapeutic alternatives.

Treatment Compliance and Adherence: In order for allergy drugs, particularly immunotherapy therapies, to work, patients need to follow long-term treatment regimens. Barriers such as exorbitant costs, intricacy, or unsatisfactory results leading to inadequate patient compliance could diminish the efficacy of therapy and hinder the market's expansion.

Healthcare Policies and Regulatory Landscape

The Pharmacy and Poisons Board (PPB), which functions under the parameters of the Pharmacy and Poisons Act, is responsible for the regulatory oversight and development of drug-related healthcare policy in Kenya. The PPB is in charge of guaranteeing the effectiveness, safety, and calibre of medicines, particularly those used in medical treatment. The board is in charge of several facets of the pharmaceutical industry, such as licensing pharmaceutical professionals, registering products, and controlling the import, distribution, and sale of medications. Another essential step in the approval process for pharmaceutical products is adherence to good manufacturing practices. By enforcing the norms and laws that control the pharmaceutical business in Kenya, the PPB plays an essential role in protecting public health.

Competitive Landscape

Key Players

• GlaxoSmithKline
• Novartis
• Sanofi
• AstraZeneca
• Bayer
• Pfizer
• Abbott
• Pharmanet Kenya Ltd.
• Mepharm Kenya Ltd.
• Mediheal Kenya Ltd.